Cirmtuzumab

[bkoffman]

Hi,

At ASH, I had the chance to interview Dr. Thomas Kipps, an expert on cirmtuzumab that targets ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1). Because ROR1 is found nearly exclusively on cancer cells, an antibody against it may be the holy grail of antibodies, one that hits only the cancer cells with few off target effects.

Please take a look at our interview: cllsociety.org

Stay strong.

We are all in this together.

Brian Koffman

[zaax]

Cirmtuzumab looks very promising

[Hidden]

That’s a very interesting study and looks promising, I’ll be interested to see how the phase 1 trials with Ibrutinib go as I’m partaking in a first line therapy with Ibrutinib/Rituximab.

It’s comforting to know as an intravenous antibody it’s toxicity levels seem to be non existent meaning it’s universally safe with no side effects.

Just out of interest was Venetoclax discussed as a combination with it or alongside Ibrutinib as a three hit combo or would that be some time off.

Are you still doing well after your trial?

Stuart

[Justasheet1 in reply to Hidden]

Great question Stuart.

[DaleFL in reply to Hidden]

I did not hear anything about that yet. But there are studies looking at other antibodies with ibrutinib and venetoclax. I hope the study is filled quickly so the results come sooner rather than later.

[bkoffman CLL CURE Hero in reply to Hidden]

I don't know of any research with it in combination with venetoclax at this time, but it's a good idea.

[Hidden in reply to bkoffman]

Hi Brian

Hope your still well.

If it’s as good as it sounds I’d put money on it as a three hit combo with I/V as a possible 6 month therapy with long remissions or possible curative.

Stuart

[gemit2000]

Hi Brian. A couple of months ago I posted a question on CAR-T using ROR1 as the target.

healthunlocked.com/cllsuppo...

With you having intimate knowledge of CAR-T as well as experience & expertise in all things CLL, would you know what happened to this MD Anderson clinical trial that Chaya Venkat referenced in her article from 6 years ago?

updates.clltopics.org/4544-...

I anticipated great results. Instead I can barely find any follow up. Seems like something didn't quite go as planned or as Chris responded to me, it perhaps "went sideways".

Thanks,

Hope the direction of CAR-T journey continues to move you forward in a positve way, (never backward or sideways)